

Pr **DOJOLVI**[®]

Triheptanoin Oral Liquid

NOVA SCOTIA

Ultragenyx Canada would like to announce that PrDOJOLVI[®] (triheptanoin) is eligible for public reimbursement in Nova Scotia for patients with LC-FAOD based on the reimbursement criteria detailed below under the Nova Scotia Pharmacare Program.

DOJOLVI[®] (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi_Final_PM.pdf for important information on contraindications, warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

The DOJOLVI[®] Reimbursement Criteria for the [Nova Scotia Pharmacare Program](#) Are as Follows:

TRihePTANOIN (Dojolvi 100% Oral Liquid)

For the treatment of adult and pediatric patients with an acute life-threatening long-chain fatty acid oxidation disorder (LC-FAOD) who meet the following criteria:

- Patients with a confirmed diagnosis of LC-FAOD and acute life-threatening events who require alternative therapy to conventional even-chain medium-chain triglyceride (MCT) supplementation OR
- Patients without a confirmed diagnosis of LC-FAOD presenting with acute life-threatening events consistent with LC-FAOD who require alternative therapy to conventional even-chain MCT supplementation

Claims Notes:*

- Triheptanoin should only be prescribed by clinicians experienced in the management of LC-FAOD.
- Approval: 1 year. Confirmation of continued response required.

* Additional claims notes available [here](#).

For more information on applying for DOJOLVI[®] coverage, we can arrange an appointment at your convenience, or you can visit the [UltraCare website](#). You can also find the [UltraCare Enrolment Form](#) on the UltraCare website.